Introduction: There is scarce evidence in literature of what should be the best antimicrobial treatment for bloodstream infections (BSIs) sustained by Stenotrophomonas maltophilia , a peculiar pathogen that intrinsically withstands to most of the available antibiotics.Results and conclusion: Here, we describe a challenging case of a persistent S. maltophilia BSI due to septic thrombosis successfully treated with the addition of the novel siderophore cephalosporin cefiderocol to an only partially effective levofloxacin regimen. Additionally, an intra-lock therapy with trimethoprim/sulfamethoxazole was selected as a strategy to prevent recurrence of infection since complete source control was not possible. The serum bactericidal assay was also used to corroborate the in vivo efficacy of the adopted combination therapy.& COPY; 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen / Medioli, Filippo; Casali, Elena; Viscido, Agnese; Pistolesi, Valentina; Venditti, Mario; Oliva, Alessandra. - In: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE. - ISSN 2213-7173. - 34:(2023), pp. 5-8. [10.1016/j.jgar.2023.05.013]

First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen

Viscido, Agnese;Pistolesi, Valentina;Venditti, Mario;Oliva, Alessandra
2023

Abstract

Introduction: There is scarce evidence in literature of what should be the best antimicrobial treatment for bloodstream infections (BSIs) sustained by Stenotrophomonas maltophilia , a peculiar pathogen that intrinsically withstands to most of the available antibiotics.Results and conclusion: Here, we describe a challenging case of a persistent S. maltophilia BSI due to septic thrombosis successfully treated with the addition of the novel siderophore cephalosporin cefiderocol to an only partially effective levofloxacin regimen. Additionally, an intra-lock therapy with trimethoprim/sulfamethoxazole was selected as a strategy to prevent recurrence of infection since complete source control was not possible. The serum bactericidal assay was also used to corroborate the in vivo efficacy of the adopted combination therapy.& COPY; 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
2023
cefiderocol; intra lock-therapy; septic thrombosis; serum bactericidal assay; stenotrophomonas maltophilia
01 Pubblicazione su rivista::01i Case report
First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen / Medioli, Filippo; Casali, Elena; Viscido, Agnese; Pistolesi, Valentina; Venditti, Mario; Oliva, Alessandra. - In: JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE. - ISSN 2213-7173. - 34:(2023), pp. 5-8. [10.1016/j.jgar.2023.05.013]
File allegati a questo prodotto
File Dimensione Formato  
Medioli_First-case_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 375.69 kB
Formato Adobe PDF
375.69 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1702887
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact